Navigation Links
YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS
Date:9/23/2007

erative efforts expand. The drug is approved in a number of Latin American countries as well as China and India.

Daiichi Sankyo Co., Ltd. in Japan, Oncoscience AG in Europe, Kuhnil Pharmaceutical Co. in South Korea and Innogene Kalbiotech in Southeast Asia have sub-licenses for nimotuzumab from CIMYM Inc., YM's majority-owned subsidiary. Cooperative trials have already been initiated with some of CIMYM's licensees and YM anticipates that the licensees will increasingly participate cooperatively to accelerate the rate of recruitment into trials of common interest, reducing the costs of development for each participant, permitting rapid recruitment and shortening the time to completion of clinical trials.

During Fiscal 2007:

- CIMYM BioSciences Inc. licensed the commercial rights for nimotuzumab

to Daiichi Sankyo Co., Ltd. for the Japanese market. The agreement

included a non-refundable up-front payment from Daiichi to the Company

of $16.2 million.

- YM BioSciences USA received clearance from the US Treasury Department

to import nimotuzumab into the US

- Daiichi Sankyo received clearance to initiate a clinical trial with

the drug in Japan.

- YM initiated enrollment for a Phase II colorectal cancer trial in

Canada. The first 50-patient cohort is expected to be completed in

calendar 2007 following which data on the primary endpoints, response

rate and safety, will be reported.

- YM received clearance to initiate a clinical trial in children with

inoperable recurrent, treatment-resistant brain cancer in Canada.

- YM reported successful regulatory review of the manufacturing of

nimotuzumab.

- YM reported preclinical data separately confirming that nimotuzumab

binds to the EGF receptor and that it also potentiates radiotherapy in

non-small-cell lung cancer cells.

Subsequent to the end of the fiscal y
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Steep Hill, the industry ... and internationally, intends to open a full service medical ... Mexico , bringing advanced scientific tools and methodology ... Steep Hill is currently the only laboratory licensed ... potency and contaminant testing in order to meet the ...
(Date:2/26/2015)... TORONTO , Feb. 26, 2015 /PRNewswire/ - SQI ... SQIDF), a life sciences company that develops and commercializes ... reported its financial and operational results for the fiscal ... this press release are in Canadian dollars (CAD), unless ... Company continued to win new business from our existing ...
(Date:2/26/2015)... The Movement for Indefinite Life Extension ... extension technologies and awareness. The event is taking place ... March 21st 2015, in a live Google Hangout broadcast ... Founder of MILE, says, “Our lives are in our ... for Indefinite Life Extension is raising awareness about bio-sciences ...
(Date:2/26/2015)... PA (PRWEB) February 26, 2015 ... 9 -12, at the Ernest N. Morial Convention ... exhibitors (count as of February 19, 2015) displaying ... in industrial, academic, and government labs. The Exposition ... as, but not limited to, analytical chemistry; drug ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3Pittcon 2015 Announces Exposition Highlights 2
... Aton Pharma, Inc., a global,specialty pharmaceutical company, ... distribution agreement with PharmaLink Asia Pacific Pte. Ltd.,to ... in Asia and,Australia., "This partnership marks an ... to expand access to our medically essential portfolio ...
... Regulatory Approval to the New York State Department of Health by Columbia ... University Medical Center,Additional West Coast ... on Rosetta Genomics, ... Two Additional microRNA-Related Patents Allowed, REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, ...
... Sankyo Co., Ltd. announced today,that it has entered into ... AG, a German biotechnology company focusing on research into,antibodies ... purchase 100 percent of the stock and make a,one-time ... the,company. Closure of the transaction is subject to clearance ...
Cached Biology Technology:Aton Pharma Announces Distribution Partnership in the Asia Pacific Region 2Rosetta Genomics Reports First Quarter 2008 Financial Results 2Rosetta Genomics Reports First Quarter 2008 Financial Results 3Rosetta Genomics Reports First Quarter 2008 Financial Results 4Rosetta Genomics Reports First Quarter 2008 Financial Results 5Rosetta Genomics Reports First Quarter 2008 Financial Results 6Rosetta Genomics Reports First Quarter 2008 Financial Results 7Rosetta Genomics Reports First Quarter 2008 Financial Results 8Rosetta Genomics Reports First Quarter 2008 Financial Results 9Rosetta Genomics Reports First Quarter 2008 Financial Results 10Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 2Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 3
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and ... reports on the recent success of the Wocket™ smart wallet at CES ... smart wallet was named as one of the "11 Hot Products at ... Products Launched At CES So Far" by Newseveryday.com and "The top 10 ...
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... from millions of years ago are recorded at daily ... A huge X-ray microscope has revealed growth bands in ... sea temperature. The results could allow scientists to ... millions of years ago. Plankton shells show features ...
... This news release is available in German . ... fatigue, loss of appetite, loss of eye lashes and eye ... effects from chemotherapy is lengthy. Many cancer patients suffer from ... cytostatic agents are injected subcutaneously or administered intravenously to halt ...
... called salvia magnesium acetate, is a phenolic acid ... molecule of caffeic acid. Salvianolic acid B exerts ... and improves energy metabolism against cerebral ischemia-reperfusion injuries. ... Second Xiangya Hospital, Central South University, China found ...
Cached Biology News:Reading ancient climate from plankton shells 2Nano-dwarves turn tumor assassins 2Nano-dwarves turn tumor assassins 3
Sold individually or included in the MasterAmp™ PCR Optimization Kit without ammonium sulfate. Includes dNTPs, buffer, and varying amounts of MgCl2 and the MasterAmp™ PCR Enhancer (with be...
Protein Marker Detection Pack contains biotinylate...
JMJD2B Antibody...
Agarose, Biotechnology grade, 500g...
Biology Products: